98%
921
2 minutes
20
Purpose: The objective of this study was to analyze the association between mean PM levels from 2000 to 2020 and the prevalence of epidermal growth factor receptor (EGFR) mutations worldwide.
Patients And Methods: We fitted linear regression models weighted by the total number of non-small cell lung cancer (NSCLC) to estimate the association strength. Adjusted R values were calculated, with values closer to 1 indicating a stronger association. Data from sixty-nine countries were available. PM data for 2015‒2020 were obtained from the Organisation for Economic Co-operation and Development database ( https://stats.oecd.org/ ). Mean PM levels, EGFR mutation prevalence data, and total NSCLC cases were acquired from published literature and national cancer registries.
Results: The association between PM levels and EGFR-mutant prevalence ranged between moderate and weak (R = 0.34, 95% Confidence interval [CI] 0.02‒0.67). The association further weakened (R < 0.15 in all comparisons) when stratified by area (European, Asian, or Latin American). Although certain countries had high air pollution and EGFR-mutant lung cancer prevalence (China: PM, 46.9% and 45.7%, respectively), the association was inconsistent.
Conclusions: The discrepancy between PM levels and the prevalence of EGFR-mutant lung cancer could be attributed to differences in access to lung cancer genomic profiling, potential over- or underestimation of EGFR-mutant prevalence, non-homogeneous PM levels within countries, inclusion of all patients with lung cancer regardless of smoking patterns, and other factors, such as genomic background and ancestry. These factors should be considered as potential limitations in directly associating PM with EGFR-mutated lung cancer development.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s12094-025-04039-0 | DOI Listing |
Oncol Res
September 2025
Department of Oncology, Affiliated Hospital of Guilin Medical University, Guilin, 541001, China.
Background: The use of third-generation different tyrosine kinase inhibitors (TKIs) is considered the most effective option for treating advanced non-small cell lung cancer (aNSCLC) with epidermal growth factor receptor (EGFR) mutations. However, there is limited information on the efficacy and safety of aumolertinib in patients remains these cases.
Methods: The clinical records of patients receiving aumolertinib as first-line therapy across four hospitals in the Guangxi Zhuang Autonomous Region from April 2020 to December 2021 were retrospectively analyzed, using progression-free survival (PFS) as the primary endpoint and overall survival (OS) representing the secondary endpoint.
Clin Transl Oncol
August 2025
GIGA/TERA Research Group (CTIC/Universidad El Bosque), Bogotá, Colombia.
Purpose: The objective of this study was to analyze the association between mean PM levels from 2000 to 2020 and the prevalence of epidermal growth factor receptor (EGFR) mutations worldwide.
Patients And Methods: We fitted linear regression models weighted by the total number of non-small cell lung cancer (NSCLC) to estimate the association strength. Adjusted R values were calculated, with values closer to 1 indicating a stronger association.
Sci Rep
August 2025
Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, Qingdao, 266000, Shandong Province, China.
Non-small cell lung cancer (NSCLC) with EGFR mutations presents a unique challenge due to the development of oligometastasis during treatment with first-line tyrosine kinase inhibitors (TKIs). The optimal timing of radiotherapy in EGFR-mutant oligometastatic NSCLC remains debated. This study aims to investigate the timing of radiotherapy in relation to disease progression to optimize treatment outcomes.
View Article and Find Full Text PDFLung Cancer
September 2025
Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People's Hospital(Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China. Electronic address:
Background: Patients withEGFR-sensitizing mutations in non-small cell lung cancer (NSCLC) predominantly receive first-line tyrosine kinase inhibitors (TKIs). Subsequent TKI resistance manifests through heterogeneous clinicopathological features, including distinct resistance subtypes (primary vs. acquired),PD-L1expression levels, and molecular profiles from re-biopsies.
View Article and Find Full Text PDFFront Med (Lausanne)
July 2025
Medical Laboratory CSD, Kyiv, Ukraine.
Introduction: Although the role of various genetic alterations was highlighted among factors affecting the response to immunotherapy in non-small cell lung cancer (NSCLC), the relations between oncogenic driver variants and changes in the cancer immunity cycle are still unclear.
Aim: The study aimed to discover the links between the molecular and immune context of NSCLC.
Materials And Methods: This cohort study included 254 cases of NSCLC (193 Lung Adenocarcinomas) (LUAD; 76%), and 61 squamous cell carcinomas (SCC; 24%), with pathology reports and next-generation sequencing (NGS) data available.